welcome
ScienceDaily

ScienceDaily

Science

Science

Immunotherapy may boost KRAS-targeted therapy in pancreatic cancer

ScienceDaily
Summary
Nutrition label

83% Informative

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy.

Nearly 90 percent of pancreatic cancers are driven by KRAS mutations , the most common cancer-causing gene mutation across cancer types, which researchers long considered "undruggable" Patients with pancreatic cancer have an overall poor prognosis.

Vonderheide is an inventor on patents relating to cancer cellular immunotherapy and KRAS immune epitopes.

The study was supported by Revolution Medicines , the National Institutes of Health , the Department of Defense , the Molecular Pathology and Imaging Core , A Love for Life , the Basser Center for BRCA and the Penn Pancreatic Cancer Research Center .

VR Score

91

Informative language

96

Neutral language

83

Article tone

formal

Language

English

Language complexity

79

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

long-living

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links

Small business owner?

Otherweb launches Autoblogger—a revolutionary way to bring more leads to any small business, using the power of AI.